Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua (MCMPFPB)
Malaria,Falciparum, Malaria, Vivax, Malaria
About this trial
This is an interventional treatment trial for Malaria,Falciparum focused on measuring Momordica charantia, primaquine, combination therapy dihydroartemisinin, Plasmodium falciparum, Plasmodium vivax
Eligibility Criteria
Inclusion Criteria: incomplete therapy patients Age ≥15 years old male or female up to 60 years old. diagnosis and an outcome inspection microscopically suffering from Plasmodium falciparum malaria or Plasmodium vivax with density parasites 1000-100,000/µL History of fever within the past 24-48 hours with axillary temperature ≥ 37.5°C There were no signs of severe malaria had no chronic disease willing to follow up for 42 days; No consuming other antimalarial drugs within 2 weeks; willingly to participate in investigations and follow established procedures (informed consent) Exclusion Criteria: pregnant female, breastfeeding female, children and infants suffering a mental disturbance, heavy illness like kidney, liver, tuberculosis, cancer, AIDS and other heavy diseases one set of symptom or signs of severe malaria had a history of hypersensitivity, allergies, and antimalarial contraindications not willingly to follow the inquiry
Sites / Locations
- Manokwari Regional General Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
bitter melon fruit extract (Momordica charantia) with primaquine
dihydroartemisinin+piperaquine+ primaquine
For three days, a combination of 500 mg of bitter melon fruit extract (Momordica charantia) and 325 mg of bitter melon fruit content (13.50 mg/kg body weight) was administered. those with Plasmodium falciparum and Plasmodium vivax malaria received a single dosage of primaquine (0.25 mg/kg body weight) once daily, with those with Plasmodium falciparum malaria receiving it for 14 days.
DHP (fixed dosage combination tablets containing 40 mg dihydroartemisinin and 320 mg piperaquine) was administered to the group for 3 days, with primaquine being administered for 14 days to patients with Plasmodium vivax and 1 day initially to those with Plasmodium falciparum without difficulties. Body weight is taken into consideration while setting therapy parameters (age 15 years, >40-60 kg: 3 tablets; >60-80 kg: 4 tablets; 80 kg: 5 tablets).